Tiroid Kanserleri I

Endocrinol Metab Clin North Am. 2007 Sep;36(3):753-78, vii.

Papillary thyroid cancer: monitoring and therapy.
Tuttle RM, Leboeuf R, Martorella AJ.

Joan and Sanford I. Weill Medical College of Cornell University, and Memorial Sloan Kettering Cancer Center, Zuckerman Building, Room 834, 1275 York Avenue,New York, NY 10021, USA. tuttlem@mskcc.org
 
The last 10 years have seen a major paradigm shift in the management of thyroid cancer, with greater reliance on serum thyroglobulin and neck ultrasonography, and less emphasis on routine diagnostic whole-body radioactive iodine scanning for detection of recurrent disease. As our follow-up tests become more sensitive for detection of recurrent disease, we are finding many asymptomatic patients who have low-level persistent disease many years after initial therapy that may or may not benefit from additional testing and therapy. These difficult issues have been addressed by at least five different sets of guidelines published recently by various thyroid specialty organizations around the world. In this article, the authors compare and contrast the recommendations from the various guidelines in an attempt to define areas of consensus and explore possible reasons for differing recommendations.

Endocrinol Metab Clin North Am. 2008 Jun;37(2):437-55, x.

Surgical approaches to thyroid tumors.
Gosnell JE, Clark OH.
University of California, San Francisco, Mt Zion Medical Center, San Francisco,CA 94143-1674, USA.

This article includes discussions of the surgical approach to benign and malignant disease and the role of prophylactic thyroidectomy and nodal dissection for medullary thyroid cancer. The controversy regarding the extent of dissection for differentiated thyroid cancer and the role of lymph node dissection are reviewed also. A description of the authors' surgical technique for thyroidectomy is detailed. Finally, several emerging technologies are introduced.

Eur J Endocrinol. 2006 Jun;154(6):787-803.

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce.

Surg Oncol Clin N Am. 2008 Jan;17(1):219-32.

The role of radiation therapy in the management of thyroid cancer.

Strasser JF, Raben A, Koprowski C.
Department of Radiation Oncology, Helen F. Graham Cancer Center, Christiana Care Health Systems, 4701 Ogletown-Stanton Rd, Newark, DE 19713, USA.
 
The goal of this article is to review the various indications for the application of external beam radiotherapy in the management of thyroid cancer. This article includes a discussion of published literature to define risk variables that increase the risk of recurrence after surgery that might be mitigated by the use of radiation therapy. Clinical outcomes, recent technologic advances in treatment planning and radiation delivery, and potential morbidity associated with treatment are also reviewed.

Endocrinol Metab Clin North Am. 2008 Jun;37(2):419-35, ix-x.

Follow up approaches in thyroid cancer: a risk adapted paradigm.
Tuttle RM, Leboeuf R.
Department of Medicine, Joan and Sanford I Weill Medical College of Cornell
University, 1300 York Avenue, New York, NY 10021, USA. tuttlem@mskcc.org

The primary goal in the follow up of thyroid cancer patients is to identify and treat persistent and recurrent disease at a time that minimizes morbidity and disease specific mortality. This article presents a risk-adapted follow-up paradigm to guide both intensity and methodology of follow-up testing based on initial risk stratification, ongoing risk stratification, and secondary risk stratification that incorporates each of the well-known risk factors for recurrence and death from thyroid cancer, with a response to therapy variable as well as duration of disease-free survival. With a proper understanding of the biology of the disease and with accurate assessments of response to therapy, clinicians are better able to tailor a risk-appropriate follow-up approach to individual patients, minimizing excessive testing while still providing adequate testing to detect clinically significant disease recurrence in a timely fashion.

World J Surg. 2007 May;31(5):895-904.

Central lymph node dissection in differentiated thyroid cancer.
White ML, Gauger PG, Doherty GM.
Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.

BACKGROUND: There has been renewed interest in extensive lymph node dissection for papillary thyroid cancer (PTC), and a number of reports have been published concerning compartment-oriented dissection of regional lymph nodes in PTC. A comprehensive review of this body of literature using evidence-based methodology is pending.
 
METHODS: Systematic review of the literature using evidence-based criteria. RESULTS: Issue 1: Systematic compartment-oriented central lymph node dissection (CLND) may decrease recurrence of PTC (Levels IV and V data, no recommendation) and likely improves disease-specific survival (grade C recommendation). Limited level III data suggest survival benefit with the addition of prophylactic dissection to thyroidectomy (grade C recommendation). The addition of CLND to total thyroidectomy can significantly reduce levels of serum thyroglobulin and increase rates of athyroglobulinemia (level IV data, no recommendation).
Issue 2:
There may be a higher rate of permanent hypoparathyroidism and unintentional permanent nerve injury when CLND is performed with total thyroidectomy than for total thyroidectomy alone (grade C recommendation). Issue 3: Reoperation in the central neck compartment for recurrent PTC may increase the risk of hypoparathyroidism and unintentional nerve injury when compared with total thyroidectomy with or without CLND (grade C recommendation), supporting a more aggressive initial operation.
CONCLUSION: Evidence-based recommendations support CLND for PTC in patients under the care of experienced endocrine surgeons.

Thyroid. 2009 Nov;19(11):1153-8.

Consensus statement on the terminology and classification of central neck
dissection for thyroid cancer.

American Thyroid Association Surgery Working Group; American Association of
Endocrine Surgeons,; American Academy of Otolaryngology-Head and Neck Surgery; American Head and Neck Society, Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, Randolph GW, Stack BC Jr, Steward DL, Terris DJ, Thompson GB, Tufano RP, Tuttle RM, Udelsman R.
 
Department of Surgery, Section of Endocrine Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
 
BACKGROUND: The primary goals of this interdisciplinary consensus statement are to review the relevant anatomy of the central neck compartment, to identify the nodal subgroups within the central compartment commonly involved in thyroid cancer, and to define a consistent terminology relevant to the central compartment neck dissection.
SUMMARY: The most commonly involved central lymph nodes in thyroid carcinoma are the prelaryngeal (Delphian), pretracheal, and the right and left paratracheal nodal basins. A central neck dissection includes comprehensive, compartment-oriented removal of the prelaryngeal and pretracheal nodes and at least one paratracheal lymph node basin. A designation should be made as to whether a unilateral or bilateral dissection is performed and on which side (left or right) in unilateral cases. Lymph node "plucking" or "berry picking" implies removal only of the clinically involved nodes rather than a complete nodal group within the compartment and is not recommended. A therapeutic central compartment neck dissection implies that nodal metastasis is apparent clinically (preoperatively or intraoperatively) or by imaging (clinically N1a). A prophylactic/elective central compartment dissection implies nodal metastasis is not detected clinically or by imaging (clinically N0).
CONCLUSION: Central neck dissection at a minimum should consist of removal of the relaryngeal, pretracheal, and paratracheal lymph nodes. The description of a central neck dissection should include both the indication (therapeutic vs. prophylactic/elective) and the extent of the dissection (unilateral or bilateral).

J Clin Endocrinol Metab. 2011 May;96(5):1202-12.

Approach to the patient with nontoxic multinodular goiter.
Bahn RS, Castro MR.
Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
Castro.Regina@mayo.edu.

Thyroid nodules are very common, and although the majority are benign, approximately 5% may harbor malignancy. The evaluation of the patient with solitary thyroid nodule is generally straightforward and will typically include measurement of serum TSH to assess thyroid function and fine-needle aspiration biopsy of the nodule, with or without ultrasound (US) guidance. The approach to the patient with nontoxic multinodular goiter represents a more difficult problem for the clinician. All patients should have serum TSH measured to assess functional thyroid status and US examination to evaluate the number, size, and sonographic features of the nodules and assist in the selection of nodules that may need fine-needle aspiration biopsy. Patients with nodules yielding malignant cytology should be referred for surgery. Given the lack of reliable markers to predict biological behavior of nodules with suspicious (indeterminate) cytology, patients with such nodules are generally advised to have surgery, unless autonomous function of these nodules can be confirmed by scintigraphy. Most of these patients, however, will ultimately prove to have benign follicular tumors. Many patients with benign but large goiters may experience clinical symptoms of pressure, such as dysphagia, choking sensation, or airway obstruction. Such patients will often require surgery for alleviation of symptoms. In the absence of malignancy, asymptomatic patients may be observed. Radioactive iodine, commonly used in many parts of Europe, is safe and effective and may be a reasonable option for many patients. Periodic follow-up with neck palpation and US exam is recommended for all patients.